Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32,127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH, Wang F. Wang ZX, et al. Among authors: he y, he j. Cancer Cell. 2022 Mar 14;40(3):277-288.e3. doi: 10.1016/j.ccell.2022.02.007. Epub 2022 Mar 3. Cancer Cell. 2022. PMID: 35245446 Free article. Clinical Trial.
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. Zhou C, et al. Among authors: he j. J Clin Oncol. 2015 Jul 1;33(19):2197-204. doi: 10.1200/JCO.2014.59.4424. Epub 2015 May 26. J Clin Oncol. 2015. PMID: 26014294 Clinical Trial.
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].
Shi Y, Sun Y, Ding C, Wang Z, Wang C, Wang Z, Bai C, Bai C, Feng J, Liu X, Li F, Yang Y, Shu Y, Wu M, He J, Zhang Y, Zhang S, Chen G, Luo H, Luo R, Zhou C, Zhou Y, Pang Q, Zhao H, Zhao Q, Gu A, Ling Y, Huang C, Han B, Jiao S, Jian H. Shi Y, et al. Among authors: he j. Zhongguo Fei Ai Za Zhi. 2015 Jul;18(7):397-400. doi: 10.3779/j.issn.1009-3419.2015.07.01. Zhongguo Fei Ai Za Zhi. 2015. PMID: 26182862 Free PMC article. Chinese. No abstract available.
Giant liposarcoma of the esophagus: A case report.
Lin ZC, Chang XZ, Huang XF, Zhang CL, Yu GS, Wu SY, Ye M, He JX. Lin ZC, et al. World J Gastroenterol. 2015 Sep 7;21(33):9827-32. doi: 10.3748/wjg.v21.i33.9827. World J Gastroenterol. 2015. PMID: 26361432 Free PMC article.
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J. Zhou C, et al. Among authors: he j. Clin Lung Cancer. 2016 Mar;17(2):119-27. doi: 10.1016/j.cllc.2015.12.002. Epub 2015 Dec 17. Clin Lung Cancer. 2016. PMID: 26781346 Clinical Trial.
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)].
Shi Y, Sun Y, Ding C, Wang Z, Wang C, Bai C, Bai C, Feng J, Liu X, Li F, Yang Y, Shu Y, Wu M, He J, Zhang Y, Zhang S, Chen G, Luo H, Luo R, Zhou C, Pang Q, Hu X, Zhao H, Zhao Q, Gu A, Ling Y, Huang C, Han B, Jiao S, Jian H. Shi Y, et al. Among authors: he j. Zhongguo Fei Ai Za Zhi. 2016 Jul 20;19(7):489-94. doi: 10.3779/j.issn.1009-3419.2016.07.12. Zhongguo Fei Ai Za Zhi. 2016. PMID: 27339727 Free PMC article. Chinese. No abstract available.
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, Li K, Wang Q, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Wang X, Luo Y, Nan K, Jin F, Li B, Chen Y, Zhou J, Wang D. Si X, et al. Among authors: he j. Lung Cancer. 2018 Aug;122:32-37. doi: 10.1016/j.lungcan.2018.05.013. Epub 2018 May 18. Lung Cancer. 2018. PMID: 30032842 Clinical Trial.
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Han B, et al. Among authors: he j. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. JAMA Oncol. 2018. PMID: 30098152 Free PMC article. Clinical Trial.
32,127 results
You have reached the last available page of results. Please see the User Guide for more information.